Nakahara Yoshiro, Mikura Shinichiro, Nagamata Makoto, Fukui Tomoya, Sasaki Jiichiro, Masuda Noriyuki
Department of Respiratory Medicine, Kitasato University School of Medicine, Sagamihara, Japan.
Department of Thoracic Oncology and Respiratory Medicine, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan.
Case Rep Oncol. 2017 May 9;10(2):428-432. doi: 10.1159/000471479. eCollection 2017 May-Aug.
Pemetrexed is a multitargeted antifolate that has demonstrated antitumor activity in non-small cell lung cancer. A 70-year-old male presented with a stage IV non-small cell lung cancer. The patient was treated with pemetrexed as third-line chemotherapy. However, a pneumothorax occurred 16 days after the administration of the second cycle of pemetrexed. The pneumothorax was slight and the patient was observed without undergoing any additional treatment. Twenty-four days after its initial occurrence, the pneumothorax had improved. This is the first case of pneumothorax that has been observed during pemetrexed treatment. Pneumothorax during chemotherapy is rare; however, it is a life-threatening complication and should not be overlooked.
培美曲塞是一种多靶点抗叶酸药物，已在非小细胞肺癌中显示出抗肿瘤活性。一名70岁男性被诊断为IV期非小细胞肺癌。该患者接受培美曲塞作为三线化疗。然而，在给予第二个周期培美曲塞后的16天发生了气胸。气胸症状较轻，对患者进行了观察，未进行任何额外治疗。气胸初次发生24天后病情有所改善。这是在培美曲塞治疗期间观察到的首例气胸病例。化疗期间发生气胸较为罕见；然而，这是一种危及生命的并发症，不容忽视。
